Indications |
Oral Prophylaxis of nausea and vomitting Adult: As maleate or mesilate: 5-10 mg bid/tid. May also be given rectally. Oral Nausea and vomiting Adult: As maleate or mesilate: 20 mg, further doses are given if needed. Recommended buccal dose: As maleate: 3-6 mg bid. Oral Psychoses Adult: As maleate or mesilate: 12.5 mg bid for 7 days, adjusted gradually to 75-100 mg daily according to response. Usual maintenance dose: 25-50 mg daily. Child: 1-5 yr: 1.25-2.5 mg; 5-12 yr: 2.5-5 mg. May be given up to tid, if necessary. Oral Adjunct in severe anxiety disorders Adult: As maleate or mesilate: 5-10 mg, up to 3-4 times daily. Oral Vertigo Adult: As maleate or mesilate: 15-30 mg daily, given in divided doses. May reduce gradually to 5-10 mg daily. Recommended buccal dose: 3-6 mg bid. Intramuscular Nausea and vomiting Adult: As mesilate: 12.5 mg by deep IM. If required, may give further doses via oral admin. Intramuscular Psychoses Adult: As mesilate: 12.5-25 mg by deep IM Inj bid/tid. Intravenous Severe nausea and vomiting Adult: As edisilate: 2.5-10 mg via slow IV inj or infusion at a rate not exceeding 5 mg/minute. Not to exceed 40 mg daily. Rectal Nausea and vomiting Adult: As base: 25 mg bid. Rectal Psychoses Adult: As maleate: 25 mg bid/tid. |
Contraindications |
CNS depression, comatose patients. Bone marrow depression, phaechromocytoma, prolactin-dependent tumours, hypersensitivity. Childn <2 yr. Pregnancy and lactation. |
Warnings / Precautions |
Extrapyramidal syndrome, hypotension, epilepsy, impaired hepatic, renal, CV, cerebrovascular or respiratory function, glaucoma. May impair ability to drive or perform tasks requiring mental alertness or physical coordination. Parenteral use in children is not recommended. History of jaundice, parkinsonism, diabetes mellitus, hypothyroidism, myasthenia gravis, paralytic ileus, prostatic hyperplasia or urinary retention. Regular eye examinations are recommended in patients on long-term treatment. |
Adverse Reactions |
Cholestatic jaundice, cardiac arrhythmias, orthostatic hypotension, leucopaenia, thrombocytopaenia, dry mouth, blurring of vision, glaucoma, urinary retention, constipation, galactorrhoea, gynaecomastia, amenorrhoea and impotence. Buccal: Transient numbness of gum and tongue. Potentially Fatal: Bone-marrow suppression. Cardiac arrhythmias or aspiration. |
Drug Interactions |
Additive anticholinergic effects with antihistamines, tricyclic antidepressants and drugs used in parkinsonism. May reduce the antihypertensive effect of guanethidine and other adrenergic neurone blockers. May also increase risk of arrhythmias when used with drugs that prolong QT interval. Potentially Fatal: Potentiation of other CNS depressants including alcohol, sedatives, hypnotics, barbiturates, opioids, antihistamines and general anaesthetics. See Below for More prochlorperazine Drug Interactions |
Food Interactions |
None reported. |
Mechanism of Actions |
Prochlorperazine blocks both postsynaptic dopamine receptors as well as the medullary chemo receptor trigger zone. It depresses hypothalamic and hypophyseal hormone release and posssesses α-adrenergic and anticholinergic inhibitory activity. |
Administration |
May be taken with or without food. |
Storage Conditions |
Intramuscular: Store below 30°C. Rectal: Store at 15-30°C. |
ATC Classification |
N05AB04 - prochlorperazine ; Belongs to the class of phenothiazine antipsychotics with piperazine structure. |
Storage |
Intramuscular: Store below 30°C. Rectal: Store at 15-30°C. |
Available As |
|
Prochlorperazine
Post Review about Prochlorperazine Click here to cancel reply.
Prochlorperazine Containing Brands
Prochlorperazine is used in following diseases
Drug - Drug Interactions of Prochlorperazine
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.